Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults (FUBEO)
The purpose of the study was to investigate whether functional MRI imaging (diffusion weighted imaging) is useful for monitoring the therapeutic response of bone sarcomas in children and young adults. All patients will be scanned before, during and after chemotherapy. The findings on MRI will be correlated with histological finding after surgery.
Second purpose : to define apparent diffusion coefficient value of the bone sarcoma.
Third purpose : to try define prognostic factors, to investigate if there is a correlation between early treatment response and outcome.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Steven Pans, MD
- Phone Number: 3216340505
- Email: steven.pans@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- University Hospitals Leuven
-
Contact:
- Steven Pans, MD
- Phone Number: 3216340505
- Email: steven.pans@uzleuven.be
-
Principal Investigator:
- Pans Steven, MD
-
Principal Investigator:
- Steven Pans, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ewing or Osteosarcoma, proven by biopsy and histopathology
- all patients are treated by chemotherapy defined by EURAMOS and EURO-EWING protocol
Exclusion Criteria:
- Patients under the age of 6 years old
- patients with contra-indication for MR exam (pace-maker...)
- Patients with renal insufficiency
- Claustrophobia
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Osteosarcoma
All patients with Osteosarcoma), proven by surgical biopsy and histopathology. All included patients will be treated by chemotherapy (EURAMOS protocol) An MRI will be performed before, during and post-treatment |
MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol. The MR findings will not have any impact on the treatment. |
|
Ewing Sarcoma
All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology. All included patients will be treated by chemotherapy (EURO-EWING protocol) An MRI will be performed in all included patients before, during and after the chemotherapy |
MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol. The MR findings will not have any impact on the treatment. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor necrosis - therapy response
Time Frame: 6 months
|
correlation of MRI findings with clinical findings during chemotherapy correlation of diffusion weighted MRI and histopathology results after surgical resection. Calculation of apparent diffusion coefficient : is it a valuable parameter? |
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prognosis and outcome
Time Frame: 2 years
|
Is there a correlation between early treatment response and outcome?
Is diffusion weighted MRI able to predict outcome of the patient (prognostic factor)?
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FUBEO
- S51516 (Other Identifier: Ethical Committee Univ.Hospital)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteosarcoma
-
NCT07144254RecruitingRefractory Osteosarcoma | Osteosarcoma Recurrent | Osteosarcoma in Children | Relapsed Osteosarcoma
-
NCT05515068Not yet recruitingOsteosarcoma | High Grade Sarcoma | Recurrent Osteosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma | Bone Tumor | Extraskeletal Osteosarcoma | Osseous Sarcoma | Parosteal Osteosarcoma | Osteoblastic Osteosarcoma
-
NCT05019703RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Unresectable Osteosarcoma | Locally Advanced Osteosarcoma
-
NCT07227571RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Advanced Osteosarcoma
-
NCT02470091CompletedRecurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma
-
NCT05683197Not yet recruitingMetastatic Osteosarcoma | Localized Osteosarcoma | Unresectable Osteosarcoma | Resectable Osteosarcoma
-
NCT02243605Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable Osteosarcoma
-
NCT01374672CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized Osteosarcoma | Osteoblastic Osteosarcoma
-
NCT05691478RecruitingMetastatic Osteosarcoma | Localized Osteosarcoma | High Grade Osteosarcoma | Secondary Osteosarcoma
-
NCT01807052CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized Osteosarcoma
Clinical Trials on MRI
-
NCT03940092Recruiting
-
NCT01880944Completed
-
NCT01882231TerminatedOsteosarcoma | Ewing Sarcoma | Paget's Disease
-
NCT03874208UnknownBrain Injury, Coma | Cardiac Arrest (CA) | Traumatic Brain Injury (TBI) | Aneurysmal Subarachnoid Hemorrhages (aSAH)
-
NCT02022579UnknownBreast Cancer | BIRADS 3 | BIRADS 4 | BIRADS 5
-
NCT04691011CompletedAmyotrophic Lateral Sclerosis
-
NCT03356366Active, not recruiting
-
NCT04649749CompletedBrachial Plexus Neuropathies | Traumatic Brachial Plexus Lesion | Bionic Hand Reconstruction